PMDA drug package insert
ザバクサ配合点滴静注用
PMDA Prescription drug · MSD株式会社 · package insert Nov 15, 2021
Key facts
| Brand names | ザバクサ配合点滴静注用 |
|---|---|
| Nonproprietary names | セフトロザン硫酸塩・タゾバクタムナトリウム |
| Companies | 製造販売元／MSD株式会社 |
| Product type | Prescription drug |
| Therapeutic category | β-ラクタマーゼ阻害剤配合抗生物質製剤 |
| Therapeutic category codes | 876139 |
| YJ codes | 6139506D1020 |
| Approval numbers | 23100AMX00005000 |
| Package insert edition | 第1版 |
| Package insert date | Nov 15, 2021 |
| PMDA document key | 170050_6139506D1020_1 |
| PMDA company code | 170050 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- Yes Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: